Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 4, 2008, Pages 798-807

  Verberne, Hein J ^a   Busemann Sokole, Ellinor ^a   Van Moerkerken, Astrid F ^a   Deeterink, Joop H W M ^a   Ensing, Geert ^b   Stabin, Michael G ^c   Somsen, G Aernout ^d   Van Eck Smit, Berthe L F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Mallinckrodt Medical   (Netherlands)

^c VANDERBILT UNIVERSITY   (United States)

^d Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

123I MIBG; Cardiology; Dosimetry; Heart failure; Sympathetic innervation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DRUG CARRIER;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSIMETRY; FEMALE; HEART NERVE; HUMAN; MALE; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SYMPATHETIC NERVE; SYMPATHETIC TONE; TISSUE DISTRIBUTION; WHOLE BODY SCINTISCANNING;

3-IODOBENZYLGUANIDINE; FEMALE; HEART; HEART CONDUCTION SYSTEM; HUMANS; INJECTIONS; IODINE RADIOISOTOPES; KINETICS; MALE; REFERENCE VALUES; SYMPATHETIC NERVOUS SYSTEM; TISSUE DISTRIBUTION; WHOLE-BODY IRRADIATION;

EID: 41049110997     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0668-y     Document Type: Article

References (36)

1. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991;350:350-4.
2. Iversen LL. The uptake of cathecholamines at high perfusion concentrations in the rat isolated heart: a novel cathecholamine uptake process. Br J Pharmac Chemother 1965;25:18-33.
3. DeGrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol 1995;22:1-12.
4. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-36.
5. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620-4.
6. Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GN, Stewart JA, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
7. Dae MW, O'Connell JW, Botvinick EH, Ahearn T, Yee E, Huberty JP, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 1989;79:634-44.
8. Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodo-benzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993;34:57-60.
9. Mangner TJ, Wu JL, Wieland DM. Solid-phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfate. J Org Biochem 1982;47:1484-8.
10. Vaidyanathan G, Zalutsky MR. No-carrier-added meta-[123I]iodo- benzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol 1995;22:61-4.
11. Verberne HJ, de Bruin K, Habraken JB, Somsen GA, Eersels JL, Moet F, et al. No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imaging 2006;33:483-90.
12. Eersels JHL, Travis MJ, Herscheid JDM. Manufacturing I-123-labelled radiopharmaceuticals. Pitfalls and solutions. J Label Comp Radiopharm 2005;48:241-257.
13. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005;32:1100-7.
14. Performance Measurements of Scintillation Cameras, NEMA Standards. Publications NU 1. 1994.
15. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
16. Brown E, Hopper J Jr., Hodges JL Jr., Bradley B, Wennesland R, Yamauchi H. Red cell, plasma, and blood volume in the healthy women measured by radiochromium cell-labeling and hematocrit. J Clin Invest 1962;41:2182-90.
17. Wennesland R, Brown E, Hopper J Jr., Hodges JL Jr., Guttentag OE, Scott KG, et al. Red cell, plasma and blood volume in healthy men measured by radiochromium (Cr51) cell tagging and hematocrit: influence of age, somatotype and habits of physical activity on the variance after regression of volumes to height and weight combined. J Clin Invest 1959;38:1065-77.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
19. Furness JB. The origin and distribution of adrenergic nerve fibres in the guinea-pig colon. Histochemie 1970;21:295-306.
20. Felten DL, Felten SY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985;135:755s-65s.
21. Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med 1997;38:447-51.
22. Samnick S, Bader JB, Muller M, Chapot C, Richter S, Schaefer A, et al. Improved labelling of no-carrier-added 123I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias. Nucl Med Commun 1999;20:537-45.
23. Knickmeier M, Matheja P, Wichter T, Schafers KP, Kies P, Breithardt G, et al. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000;27:302-7.
24. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 2004;11:126-33.
25. Jacobsson L, Mattson S, Johansson L, Lindberg S, Fjälling M. Biokinetics and dosimetry of 131I-metaiodobenzylguanidine (MIBG). Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge 1985. Oak Ridge National Laborotories, Oak Ridge, Tennessee: Oak Ridge Assoc. Universities CONF-851113; 1986. p. 389-98.
26. Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP 1987;18:1-377.
27. Valentin J. Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997. Ann ICRP 1998;28:1-121.
28. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Oxford: Pergamon Press; 1991.
29. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in The Netherlands. Health Phys 1988;54:287-91.
30. Ngutter LK, Kofler JM, McCollough CH, Vetter RJ. Update on patient radiation doses at a large tertiary care medical center. Health Phys 2001;81:530-5.
31. Radiation dose to patients from radiopharmaceuticals: A report of Committee 3 adopted by the International Commission on Radiological Protection. Ann ICRP 1991;22:1-18.
32. Bonow RO, Bennett S, Casey DE Jr., Ganiats TG, Hlatky MA, Konstam MA, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2005;46:1144-78.
33. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 2005;112:1888-916.
34. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
35. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
36. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.